Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease

Sokolova S.V.; Sozarukova M.M.; Khannanova A.N.; Grishina N.K.; Portnova G.V.; Proskurnina E.V.

doi:https://doi.org/10.17116/jnevro202012006182

Sokolova S.V.

Lomonosov Moscow State University, Medical Research and Educational Center

Sozarukova M.M.

Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences

Khannanova A.N.

Gilyarovsky Psychiatric Hospital, the branch of the Psychiatric Clinical Hospital No. 4 of the Moscow Health Department

ORCID: 0000-0002-5765-2259

Grishina N.K.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Portnova G.V.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Proskurnina E.V.

Research Centre of Medical Genetics

Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease

Authors:

Sokolova S.V., Sozarukova M.M., Khannanova A.N., Grishina N.K., Portnova G.V., Proskurnina E.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6): 82‑87

DOI: 10.17116/jnevro202012006182

Read: 4820 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sokolova SV, Sozarukova MM, Khannanova AN, Grishina NK, Portnova GV, Proskurnina EV. Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):82‑87. (In Russ.)
https://doi.org/10.17116/jnevro202012006182

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the antioxidant profile of blood plasma in patients with paranoid schizophrenia and Alzheimer disease (AD).

MATERIAL AND METHODS

Thirty-three patients with paranoid schizophrenia and 18 patients with AD were included in the study. Patients with schizophrenia were stratified into two subgroups by response to therapy. The indicators of the antioxidant profile were determined using methods based on chemiluminometry and spectrofluorimetry.

RESULTS

Systemic oxidative stress due to insufficiency of low molecular weight plasma antioxidants is not determined neither in AD nor in treatment resistant schizophrenia. At the same time, a «thiol» oxidative stress, which indirectly indicates a deficiency of the glutathione system, is present in both groups. In patients with paranoid schizophrenia responsive to treatment, systemic oxidative stress is more pronounced and «thiol» oxidative stress is less significant. Among the antipsychotics studied, haloperidol, zuclopenthixol, risperidone and ziprasidone do not exhibit antioxidant properties, but periciazine, clozapine and especially chlorpromazine exhibit strong antioxidant properties, but they unlikely affect the antioxidant potential of blood plasma.

CONCLUSIONS

The glutathione part of the antioxidant system is mostly affected, but systemic oxidative stress is not significant in patients with treatment resistant paranoid schizophrenia and AD. Oxidative disorders are more pronounced in treatment responsive paranoid schizophrenia.

Keywords:

antioxidant status

paranoid schizophrenia

Alzheimer disease

Authors:

Sokolova S.V.

Lomonosov Moscow State University, Medical Research and Educational Center

Sozarukova M.M.

Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences

Khannanova A.N.

Gilyarovsky Psychiatric Hospital, the branch of the Psychiatric Clinical Hospital No. 4 of the Moscow Health Department

ORCID: 0000-0002-5765-2259

Grishina N.K.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Portnova G.V.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Proskurnina E.V.

Research Centre of Medical Genetics

Received:

03.11.2019

Accepted:

31.01.2020

Close metadata

References:

Ruiz-Litago F, Seco J, Echevarria E, Martinez-Cengotitabengoa M, Gil J, Irazusta J, Gonzalez-Pinto AM. Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study. Psychiatry Res. 2012;200:218-222. https://doi.org/10.1016/j.psychres.2012.07.024
Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011-2035. https://doi.org/10.1089/ars.2010.3603
Magalhaes PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:CD008919. https://doi.org/10.1002/14651858.cd008919.pub2
Xie T, Li Q, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Tan Y. Plasma total antioxidant status and cognitive impairments in first-episode drug-naive patients with schizophrenia. Cogn Neurodyn. 2019;13:357-365. https://doi.org/10.1007/s11571-019-09530-3
Li XF, Zheng YL, Xiu MH, Chen DC, Kosten TR, Zhang XY. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1064-1067. https://doi.org/10.1016/j.pnpbp.2011.03.001
Reyazuddin M, Azmi SA, Islam N, Rizvi A. Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics. Indian J Psychiatry. 2014;56:344-349.
Zhang XY, Chen DC, Xiu MH, Tang W, Zhang F, Liu L, Chen Y, Liu J, Yao JK, Kosten TA, Kosten TR. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res. 2012;139:66-72. https://doi.org/10.1016/j.schres.2012.04.009
Miljevic CD, Nikolic-Kokic A, Blagojevic D, Milovanovic M, Munjiza A, Jukic MM, Pesic V, Lecic-Tosevski D, Spasic MB. Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res. 2018;269:746-752. https://doi.org/10.1016/j.psychres.2018.09.009
Das TK, Javadzadeh A, Dey A, Sabesan P, Theberge J, Radua J, Palaniyappan L. Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. Prog Neuropsychopharmacol Biol Psychiatry. 2019;91:94-102. https://doi.org/10.1016/j.pnpbp.2018.08.006
Zhang Y, Catts VS, Weickert CSh. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust N Z J Psychiatry. 2018; 52:690-698. https://doi.org/10.1177/0004867417728805
Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal. 2011;15:2057-2065. https://doi.org/10.1089/ars.2010.3453
Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80:29-39. https://doi.org/10.1016/s0165-1781(98)00051-1
Sadowska-Bartosz I, Galiniak S, Bartosz G, Zuberek M, Grzelak A, Dietrich-Muszalska A. Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia. Schizophr Res. 2016;176:245-251. https://doi.org/10.1016/j.schres.2016.07.010
Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479:317-320. https://doi.org/10.1016/j.neulet.2010.05.088
Pohanka M. Oxidative stress in Alzheimer disease as a target for therapy. Bratisl Lek Listy. 2018;119:535-543. https://doi.org/10.4149/bll_2018_097
Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid beta-peptide 1-42. Peptides. 2002;23:1299-1309. https://doi.org/10.1016/s0196-9781(02)00066-9
Exley C, House E, Polwart A, Esiri MM. Brain burdens of aluminum, iron, and copper and their relationships with amyloid-beta pathology in 60 human brains. J Alzheimers Dis. 2012;31:725-730. https://doi.org/10.3233/jad-2012-120766
Roberts AM, Jagadapillai R, Vaishnav RA, Friedland RP, Drinovac R, Lin X, Gozal E. Increased pulmonary arteriolar tone associated with lung oxidative stress and nitric oxide in a mouse model of Alzheimer’s disease. Physiol Rep. 2016;4:e12953. https://doi.org/10.14814/phy2.12953
Nesi G, Sestito S, Digiacomo M, Rapposelli S. Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer’s Disease. Curr Top Med Chem. 2017;17:3062-3079. https://doi.org/10.2174/1568026617666170607114232
Mandal PK, Tripathi M, Sugunan S. Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun. 2012;417:43-48. https://doi.org/10.1016/j.bbrc.2011.11.047
Allen M, Zou F, Chai HS, Younkin CS, Miles R, Nair AA, Crook JE, Pankratz VS, Carrasquillo MM, Rowley CN, Nguyen T, Ma L, Malphrus KG, Bisceglio G, Ortolaza AI, Palusak R, Middha S, Maharjan S, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Sando SB, Aasly JO, Barcikowska M, Uitti RJ, Wszolek ZK, Ross OA, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Mol Neurodegener. 2012;7:13. https://doi.org/10.1186/1750-1326-7-13
Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, Gokhman D, Gasiorowski K, Bragin V, Aliev G. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. CNS Neurol Disord Drug Targets. 2011;10:149-162. https://doi.org/10.2174/187152711794480474
Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta. 2012;1822:625-630. https://doi.org/10.1016/j.bbadis.2011.10.003
Zampagni M, Wright D, Cascella R, D’Adamio G, Casamenti F, Evangelisti E, Cardona F, Goti A, Nacmias B, Sorbi S, Liguri G, Cecchi C. Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radic Biol Med. 2012;52:1362-1371. https://doi.org/10.1016/j.freeradbiomed.2012.01.012
Andreasen NC, Carpenter WT-Jr, Kane JM, Lasser AR, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. https://doi.org/10.1176/appi.ajp.162.3.441
Alekseev AV, Proskurnina EV, Vladimirov YuA. Determination of Antioxidants by Sensitized Chemiluminescence Using 2,2’-azo-bis(2-amidinopropane). Moscow Univ Chem Bull. 2012;53(3):187-193. (In Russ.). https://doi.org/10.3103/s0027131412030029
Liu H, Wang H, Shenvi S, Hagen TM, Liu RM. Glutathione metabolism during aging and in Alzheimer disease. Ann N Y Acad Sci. 2004;1019:346-349. https://doi.org/10.1196/annals.1297.059
Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Ciappi F, Bria P, Caltagirone C, Bossu P. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatry. 2007;15:879-887. https://doi.org/10.1097/jgp.0b013e3180547076
Capurso C, Panza F, Seripa D, Frisardi V, Imbimbo BP, Verdile G, Vendemiale G, Pilotto A, Solfrizzi V. Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease. Rejuvenation Res. 2010;13:645-652. https://doi.org/10.1089/rej.2010.1052
Porokhovnik LN, Pasekov VP, Yegolina NA, Tzvetkova TG, Kosyakova NV, Gorbachevskaya NL, Sukhotina NK, Kozlovskaya GV, Sorokin AB, Korovina NYu, Lyapunova NA. Oxidative stress, rRNA genes, and antioxidant enzymes in pathogenesis of schizophrenia and autism: Modeling and clinical recommendations. Biol Bull Rev. 2014;4(5):340-353. (In Russ.). https://doi.org/10.1134/s2079086414050065]